Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2017 February;108(1) > Minerva Medica 2017 February;108(1):28-42

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Medica 2017 February;108(1):28-42

DOI: 10.23736/S0026-4806.16.04864-3

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Screening for Barrett’s esophagus

Liam ZAKKO, Lori LUTZKE, Kenneth K. WANG

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA


PDF


Barrett’s esophagus is the only known esophageal precursor for the development of esophageal adenocarcinoma. However, screening for Barrett’s esophagus remains controversial. Although screening is advocated in selected populations, it is unclear how it should be implemented. In this review, the current definition of Barrett’s esophagus will be discussed. There will be a review of the emerging evidence supporting the cost-effectiveness of screening and surveillance for Barrett’s esophagus in preventing esophageal adenocarcinoma. The known risk factors for Barrett’s esophagus and the development of esophageal adenocarcinoma, currently utilized to determine the appropriate populations to screen, will be reviewed. Finally we will review the standard techniques utilized to screen for Barrett’s esophagus and examine new technologies that might improve the efficacy and availability of Barrett’s esophagus screening.


KEY WORDS: Barrett esophagus - Mass screening - Adenocarcinoma of esophagus

inizio pagina